{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:04:19Z","timestamp":1792116259321,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013798","name":"Jiangxi Science and Technology Normal University","doi-asserted-by":"publisher","award":["2023BSQD41"],"award-info":[{"award-number":["2023BSQD41"]}],"id":[{"id":"10.13039\/501100013798","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012131","name":"Department of Science and Technology of Liaoning Province","doi-asserted-by":"publisher","award":["2024-MS-226"],"award-info":[{"award-number":["2024-MS-226"]}],"id":[{"id":"10.13039\/501100012131","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021183","name":"Science Fund for Distinguished Young Scholars of Jiangxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021183","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Jiangxi Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["20242BAB23092"],"award-info":[{"award-number":["20242BAB23092"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.118932","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:23:23Z","timestamp":1778891003000},"page":"118932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["CADD-based discovery of novel heterocyclic pyrimidine-based CDK4\/6 inhibitors: Design, synthesis, and anti-breast cancer activity studies"],"prefix":"10.1016","volume":"315","author":[{"given":"Xinya","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shidi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanrui","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dajun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9999-9899","authenticated-orcid":false,"given":"Shan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118932_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.118932_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17172830","article-title":"Lifestyle and breast cancer: prevention and treatment support","volume":"17","author":"Ratajczak-Paw\u0142owska","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.118932_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202514085","article-title":"Emerging nanozyme strategies for precision breast cancer treatment","volume":"12","author":"Zang","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejmech.2026.118932_bib4","article-title":"Tumor-associated neutrophils in breast cancer: an angel or a devil?","volume":"16","author":"Wen","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118932_bib5","doi-asserted-by":"crossref","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","article-title":"Cancer treatment therapies: traditional to modern approaches to combat cancers","volume":"50","author":"Kaur","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ejmech.2026.118932_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s43018-021-00192-x","article-title":"Advancing cancer therapy","volume":"2","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ejmech.2026.118932_bib7","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/jcb.25782","article-title":"Therapeutic potential of small molecule inhibitors","volume":"118","author":"Khera","year":"2017","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ejmech.2026.118932_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114819","article-title":"The development of small-molecule inhibitors targeting HPK1","volume":"244","author":"Zhou","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118932_bib9","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.apsb.2021.12.022","article-title":"Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy","volume":"12","author":"Pan","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.118932_bib10","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2023.5476","article-title":"Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment","volume":"62","author":"Jin","year":"2023","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2026.118932_bib11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.apsb.2020.05.004","article-title":"Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.118932_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104053","article-title":"Small molecular inhibitors: therapeutic strategies for pancreatic cancer","volume":"29","author":"Golivi","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.118932_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114759","article-title":"TLR8 agonist Motolimod-induced inflammatory death for treatment of acute myeloid leukemia","volume":"163","author":"Yang","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.118932_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112993","article-title":"PROTACs to address the challenges facing small molecule inhibitors","volume":"210","author":"Martin-Acosta","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118932_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231205848","article-title":"CDK4\/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity - a narrative review","volume":"15","author":"Pavlovic","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ejmech.2026.118932_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.575","article-title":"PROteolysis-Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives","volume":"5","author":"Vicente","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.ejmech.2026.118932_bib17","doi-asserted-by":"crossref","DOI":"10.15252\/msb.20188604","article-title":"Evidence that the human cell cycle is a series of uncoupled, memoryless phases","volume":"15","author":"Chao","year":"2019","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.ejmech.2026.118932_bib18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118932_bib19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s43018-024-00893-z","article-title":"Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer","volume":"6","author":"Asciolla","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ejmech.2026.118932_bib20","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40265-015-0379-9","article-title":"Palbociclib: first global approval","volume":"75","author":"Dhillon","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118932_bib21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40265-017-0742-0","article-title":"Ribociclib: first global approval","volume":"77","author":"Syed","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118932_bib22","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s40265-017-0840-z","article-title":"Abemaciclib: first global approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118932_bib23","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future","volume":"395","author":"Spring","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118932_bib24","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40259-019-00382-1","article-title":"Different cardiotoxicity of palbociclib and ribociclib in breast cancer: gene expression and pharmacological data analyses, biological basis, and therapeutic implications","volume":"33","author":"Santoni","year":"2019","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejmech.2026.118932_bib25","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1158\/1535-7163.MCT-21-0411","article-title":"Cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with ralaniten analogs for the treatment of androgen receptor-positive prostate and breast cancers","volume":"21","author":"Tien","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.118932_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/biom13091422","article-title":"An overview of the safety profile and clinical impact of CDK4\/6 inhibitors in breast Cancer-A systematic review of randomized phase II and III clinical trials","volume":"13","author":"Stanciu","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2026.118932_bib27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41420-025-02493-x","article-title":"CDK4\/6-mediated phosphorylation of DUB3 promotes YAP1 stability and hepatocellular carcinoma progression","volume":"11","author":"Huang","year":"2025","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ejmech.2026.118932_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10030685","article-title":"Targeting CDK4\/6 for anticancer therapy","volume":"10","author":"Qi","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2026.118932_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.138189","article-title":"Design, synthesis, and antitumor activity of benzimidazole derivatives as CDK4\/6 inhibitors","volume":"1309","author":"Wang","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2026.118932_bib30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejmech.2018.02.022","article-title":"Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4\/6 inhibitors for cancer therapy","volume":"148","author":"Zha","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118932_bib31","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1158\/1535-7163.MCT-16-0300","article-title":"Spectrum and degree of CDK drug interactions predicts clinical performance","volume":"15","author":"Chen","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.118932_bib32","first-page":"756","article-title":"Ganoderic acid a derivative induces apoptosis of cervical cancer cells by inhibiting JNK pathway","volume":"17","author":"Wang","year":"2025","journal-title":"Chin Herb Med"},{"key":"10.1016\/j.ejmech.2026.118932_bib33","first-page":"94","article-title":"Magnolol and 5-fluorouracil synergy inhibition of metastasis of cervical cancer cells by targeting PI3K\/AKT\/mTOR and EMT pathways","volume":"16","author":"Chen","year":"2024","journal-title":"Chin Herb Med"},{"key":"10.1016\/j.ejmech.2026.118932_bib34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13046-025-03627-w","article-title":"Targeting serine synthesis pathway to reverse paclitaxel resistance in NSCLC with combination of paclitaxel and anlotinib","volume":"45","author":"Yu","year":"2026","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:57:28Z","timestamp":1783058248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426003776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":34,"alternative-id":["S0223523426003776"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118932","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CADD-based discovery of novel heterocyclic pyrimidine-based CDK4\/6 inhibitors: Design, synthesis, and anti-breast cancer activity studies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118932","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118932"}}